Guadecitabine

Name: Guadecitabine
Brand: TargetMol
SKU: T16876
Rating: 4.5 (1 reviews)

Copy Product Info

😃Good

Catalog No. T16876Cas No. 929901-49-5

Alias SGI-110

Guadecitabine is a second-generation DNA methyltransferases inhibitor. It is used for research on acute myeloid leukemia and myelodysplastic syndromes.

Guadecitabine

Copy Product Info

😃Good

Catalog No. T16876Alias SGI-110Cas No. 929901-49-5

Guadecitabine is a second-generation DNA methyltransferases inhibitor. It is used for research on acute myeloid leukemia and myelodysplastic syndromes.

Pack Size	Price	USA Warehouse	Global Warehouse
25 mg	Inquiry	6-8 weeks	6-8 weeks
50 mg	Inquiry	6-8 weeks	6-8 weeks
100 mg	Inquiry	6-8 weeks	6-8 weeks

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Resource Download

Product Introduction

Bioactivity

Description	Guadecitabine is a second-generation DNA methyltransferases inhibitor. It is used for research on acute myeloid leukemia and myelodysplastic syndromes.
In vitro	Exposure to Guadecitabine significantly enhances the expression levels of HLA class I antigens, specifically HLA-A2 allospecificity, and the co-stimulatory molecule ICAM-1 in Mel 275 melanoma cells, indicating an upregulation (p<0.05). Additionally, it notably reduces the methylation levels of CTA promoters in the cancer cells studied, leading to a significant decrease (p<0.01). This exposure also stimulates the expression of previously non-expressed cancer/testis antigens in CTA-negative cancer cells and markedly increases MAGE-A3- and NY-ESO-1-specific mRNA expression across all investigated neoplastic cell histotypes. Furthermore, Guadecitabine's induction of demethylation in MAGE-A1 and NY-ESO-1 promoters shows mean values of 57% and 30% in Mel 195 cells, and 22% and 33% in MZ-1257 RCC cells, respectively.
In vivo	Guadecitabine effectively inhibits tumor growth with significantly lower toxicity levels, as evident through less weight change in mice, when administered subcutaneously (SQ) compared to intraperitoneal (IP) injections. Although Guadecitabine does not reduce tumor size, it markedly restricts their growth, in contrast to tumors receiving only PBS, which exhibit considerable enlargement [3].
Synonyms	SGI-110

Chemical Properties

Molecular Weight	557.41
Formula	C₁₈H₂₄N₉O₁₀P
Cas No.	929901-49-5
Smiles	O=C1C2=C(N(C=N2)[C@@H]3O[C@H](COP(O[C@@H]4[C@@H](CO)O[C@H](C4)N5C(=O)N=C(N)N=C5)(=O)O)[C@@H](O)C3)NC(N)=N1
Relative Density.	2.24±0.1 g/cm3 (20 °C, 760 mmHg)

Storage & Solubility Information

Storage	Powder: -20°C for 3 years \| Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	H2O: Soluble

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc